‌

US Patent 6887471 Method to inhibit T cell interactions with soluble B7

Patent 6887471 was granted and assigned to Bristol-Myers Squibb on May, 2005 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

1

Patent attributes

Patent Applicant

Loading...

1

Current Assignee

Bristol-Myers Squibb

1

Patent Jurisdiction

United States Patent and Trademark Office

1

Patent Number

Patent Inventor Names

Nitin K. Damle1

Jeffrey A. Ledbetter1

Peter S. Linsley1

William Brady1

Date of Patent

May 3, 2005

1

Patent Application Number

094546511

Date Filed

December 6, 1999

1

Patent Citations Received

US Patent 11834490 CD112 variant immunomodulatory proteins and uses thereof

2

US Patent 12065476 PD-1 variant immunomodulatory proteins and uses thereof

3

US Patent 12110339 ICOS ligand variant immunomodulatory proteins and uses thereof

4

Patent Primary Examiner

1

Patent abstract

This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 6887471 Method to inhibit T cell interactions with soluble B7

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.